ECT Schizophrenia Serotonin Study

May 20, 2008 updated by: Sha'ar Menashe Mental Health Center

Serotonin Uptake to Lymphocytes and Citalopram Platelets Binding of Treatment-Resistant Schizophrenia Patients Before and After Electroconvulsive Therapy

We suggest to investigate serotonin uptake in schizophrenia patients receiving ECT

Study Overview

Status

Unknown

Conditions

Detailed Description

We suggest to investigate serotonin uptake in schizophrenia patients receiving ECT

Study Type

Observational

Enrollment (Anticipated)

15

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Participants must meet DSM-IV criteria for schizophrenia, as assessed by the Structured Clinical Interview - Patient Version (SCID) (First et al., 1995).

Ages 18 -55 Men and/or women -

Exclusion Criteria:

  1. History of neurological disorders, active substance abuse in the previous 3 months.
  2. Estimated IQ less then 70.
  3. SSRIs treatment 4 weeks prior to the study.

  4. Any subject suffering from inflammatory fever disease will be excluded from the study.

    -

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sha'ar Menashe Mental Health Center

Investigators

  • Principal Investigator: Avi Peled, MD, Shaar Menashe MHC
  • Principal Investigator: Ilan Modai, M.D. MHA, Shaar Menashe
  • Principal Investigator: Moshe Rehavi, Ph.D., TAU

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2006

Study Completion (Anticipated)

October 1, 2006

Study Registration Dates

First Submitted

January 16, 2006

First Submitted That Met QC Criteria

January 16, 2006

First Posted (Estimate)

January 18, 2006

Study Record Updates

Last Update Posted (Estimate)

May 21, 2008

Last Update Submitted That Met QC Criteria

May 20, 2008

Last Verified

May 1, 2008

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 123.ctil

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Schizophrenia

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe